BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 33369998)

  • 1. Altered von Willebrand Factor and ADAMTS13 Levels in Children With Cirrhosis and Extrahepatic Portal Hypertension.
    Islek A; Ilhan D; Ozturk N; Guven B; Sag E
    J Pediatr Hematol Oncol; 2021 Oct; 43(7):e951-e956. PubMed ID: 33369998
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Levels and activities of von Willebrand factor and metalloproteinase with thrombospondin type-1 motif, number 13 in inflammatory bowel diseases.
    Cibor D; Owczarek D; Butenas S; Salapa K; Mach T; Undas A
    World J Gastroenterol; 2017 Jul; 23(26):4796-4805. PubMed ID: 28765701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased von Willebrand factor ristocetin cofactor activity and increased ADAMTS13 antigen increase postoperative drainage after coronary artery bypass grafting.
    Mazur P; Plicner D; Zdziarska J; Sadowski J; Undas A
    Eur J Cardiothorac Surg; 2014 Feb; 45(2):e26-32. PubMed ID: 24351199
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Imbalance of von Willebrand factor and its cleaving protease ADAMTS13 during systemic inflammation superimposed on advanced cirrhosis.
    Reuken PA; Kussmann A; Kiehntopf M; Budde U; Stallmach A; Claus RA; Bruns T
    Liver Int; 2015 Jan; 35(1):37-45. PubMed ID: 25113276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome.
    Simbrunner B; Villesen IF; Scheiner B; Paternostro R; Schwabl P; Stättermayer AF; Marculescu R; Pinter M; Quehenberger P; Trauner M; Karsdal M; Lisman T; Reiberger T; Leeming DJ; Mandorfer M
    Hepatol Int; 2023 Dec; 17(6):1532-1544. PubMed ID: 37605068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADAMTS13 missense variants associated with defective activity and secretion of ADAMTS13 in a patient with non-cirrhotic portal hypertension.
    Goel A; Raghupathy V; Amirtharaj GJ; Chapla A; Venkatraman A; Ramakrishna B; Ramachandran A; Thomas N; Balasubramanian KA; Mackie I; Elias E; Eapen CE
    Indian J Gastroenterol; 2017 Sep; 36(5):380-389. PubMed ID: 28980147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of the Diagnostic Value of Plasma Levels, Activities, and Their Ratios of von Willebrand Factor and ADAMTS13 in Patients with Cerebral Infarction.
    Qu L; Jiang M; Qiu W; Lu S; Zhao Y; Xia L; Ruan C; Zhao Y
    Clin Appl Thromb Hemost; 2016 Apr; 22(3):252-9. PubMed ID: 25916953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High von Willebrand factor levels increase the risk of first ischemic stroke: influence of ADAMTS13, inflammation, and genetic variability.
    Bongers TN; de Maat MP; van Goor ML; Bhagwanbali V; van Vliet HH; Gómez García EB; Dippel DW; Leebeek FW
    Stroke; 2006 Nov; 37(11):2672-7. PubMed ID: 16990571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activity of Von Willebrand factor and levels of VWF-cleaving protease (ADAMTS13) in preterm and full term neonates.
    Strauss T; Elisha N; Ravid B; Rosenberg N; Lubetsky A; Levy-Mendelovich S; Morag I; Nowak Göttl U; Kenet G
    Blood Cells Mol Dis; 2017 Sep; 67():14-17. PubMed ID: 28087247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The ADAMTS13-von Willebrand factor axis in COVID-19 patients.
    Mancini I; Baronciani L; Artoni A; Colpani P; Biganzoli M; Cozzi G; Novembrino C; Boscolo Anzoletti M; De Zan V; Pagliari MT; Gualtierotti R; Aliberti S; Panigada M; Grasselli G; Blasi F; Peyvandi F
    J Thromb Haemost; 2021 Feb; 19(2):513-521. PubMed ID: 33230904
    [TBL] [Abstract][Full Text] [Related]  

  • 11. von Willebrand Factor Antigen, von Willebrand Factor Propeptide, and ADAMTS13 in Carotid Stenosis and Their Relationship with Cerebral Microemboli.
    Murphy SJX; Lim ST; Hickey F; Kinsella JA; Smith DR; Tierney S; Egan B; Feeley TM; Murphy SM; Collins DR; Coughlan T; O'Neill D; Harbison JA; Madhavan P; O'Neill SM; Colgan MP; O'Donnell JS; O'Sullivan JM; Hamilton G; McCabe DJH
    Thromb Haemost; 2021 Jan; 121(1):86-97. PubMed ID: 32932544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Major Changes of von Willebrand Factor Multimer Distribution in Cirrhotic Patients with Stable Disease or Acute Decompensation.
    Palyu E; Harsfalvi J; Tornai T; Papp M; Udvardy M; Szekeres-Csiki K; Pataki L; Vanhoorelbeke K; Feys HB; Deckmyn H; Tornai I
    Thromb Haemost; 2018 Aug; 118(8):1397-1408. PubMed ID: 29972862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADAMTS13 deficiency, despite well-compensated liver functions in patients with noncirrhotic portal hypertension.
    Goel A; Alagammai PL; Nair SC; Mackie I; Ramakrishna B; Muliyil J; Keshava SN; Eapen CE; Elias E
    Indian J Gastroenterol; 2014 Jul; 33(4):355-63. PubMed ID: 24756423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of von Willebrand factor and ADAMTS13 in patients with COVID-19: A systematic review and meta-analysis.
    Xu X; Feng Y; Jia Y; Zhang X; Li L; Bai X; Jiao L
    Thromb Res; 2022 Oct; 218():83-98. PubMed ID: 36027630
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased von Willebrand factor over decreased ADAMTS13 activity may contribute to the development of liver disturbance and multiorgan failure in patients with alcoholic hepatitis.
    Matsuyama T; Uemura M; Ishikawa M; Matsumoto M; Ishizashi H; Kato S; Morioka C; Fujimoto M; Kojima H; Yoshiji H; Takimura C; Fujimura Y; Fukui H
    Alcohol Clin Exp Res; 2007 Jan; 31(1 Suppl):S27-35. PubMed ID: 17331163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A two-centre comparative evaluation of new automated assays for von Willebrand factor ristocetin cofactor activity and antigen.
    Stufano F; Lawrie AS; La Marca S; Berbenni C; Baronciani L; Peyvandi F
    Haemophilia; 2014 Jan; 20(1):147-53. PubMed ID: 24028703
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Associations between the von Willebrand Factor-ADAMTS13 Axis, Complement Activation, and COVID-19 Severity and Mortality.
    Sinkovits G; Réti M; Müller V; Iványi Z; Gál J; Gopcsa L; Reményi P; Szathmáry B; Lakatos B; Szlávik J; Bobek I; Prohászka ZZ; Förhécz Z; Mező B; Csuka D; Hurler L; Kajdácsi E; Cervenak L; Kiszel P; Masszi T; Vályi-Nagy I; Prohászka Z
    Thromb Haemost; 2022 Feb; 122(2):240-256. PubMed ID: 35062036
    [TBL] [Abstract][Full Text] [Related]  

  • 18. VWF/ADAMTS13 ratio as a potential biomarker for early detection of hepatocellular carcinoma.
    Takaya H; Namisaki T; Kitade M; Kaji K; Nakanishi K; Tsuji Y; Shimozato N; Moriya K; Seki K; Sawada Y; Saikawa S; Sato S; Kawaratani H; Akahane T; Noguchi R; Matsumoto M; Yoshiji H
    BMC Gastroenterol; 2019 Oct; 19(1):167. PubMed ID: 31638892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Von Willebrand factor (VWF) activity VWF:Ac with VWF ristocetin cofactor activity VWF:RCo.
    Geisen U; Zieger B; Nakamura L; Weis A; Heinz J; Michiels JJ; Heilmann C
    Thromb Res; 2014 Aug; 134(2):246-50. PubMed ID: 24891215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Ratio of von Willebrand Factor Antigen to ADAMTS13 Activity: Usefulness as a Prognostic Biomarker in Acute-on-Chronic Liver Failure.
    Takaya H; Namisaki T; Enomoto M; Kubo T; Tsuji Y; Fujinaga Y; Nishimura N; Kaji K; Kawaratani H; Moriya K; Akahane T; Matsumoto M; Yoshiji H
    Biology (Basel); 2023 Jan; 12(2):. PubMed ID: 36829443
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.